# A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)

Source: https://onco.cc/trials/nct07554456/  
OnCo record `nct07554456` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Tislelizumab and Cisplatin in oesophageal cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02) is a phase 2/3 interventional study registered as NCT07554456 by Sichuan Baili Pharmaceutical Co., Ltd., with 90 participants planned, started 2026-06-09 and due to reach its primary completion in 2028-12. Interventions recorded: BL-B01D1, Tislelizumab, 5-Fluorouracil, Cisplatin and Paclitaxel.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07554456
- Phase: 2/3
- Setting: A Phase II/III Randomized Controlled Clinical Study of BL-B01D1 for Injection in Combination With Tislelizumab With or Without 5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Enrolled: 90

## Sources

- ClinicalTrials.gov NCT07554456: https://clinicaltrials.gov/study/NCT07554456

## Connected records

- cancers: [Oesophageal cancer](https://onco.cc/cancers/esophageal/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- companies: [SystImmune / Sichuan Biokin](https://onco.cc/companies/systimmune/)

---
JSON: https://onco.cc/api/v1/entities/nct07554456.json